查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2024190

感染疾病臨床檢查室分子診斷市場：按應用、地區和國家分類的策略、趨勢和預測 - 市場分析和管理指南（2026-2030 年）

Clinical Laboratory Molecular Diagnostics for Infectious Disease Markets. Strategies and Trends. Forecasts by Application by Place and by Country. With Market Analysis & Executive Guides. 2026 to 2030
出版日期: | 出版商: Howe Sound Research | 英文 356 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

報告摘要：

傳染病檢查診斷是臨床檢測市場中最具活力和戰略意義的領域之一。這些診斷技術透過檢測與病毒、細菌、真菌和寄生蟲等病原體相關的核酸，能夠快速、高精度地識別病原體。與傳統的微生物學方法相比，分子診斷在靈敏度和特異性方面具有顯著優勢，且出結果所需時間更短，使臨床醫生能夠更快地啟動適當的治療，並控制感染疾病的傳播。

全球感染疾病臨床檢查室分子診斷市場規模估計每年超過120億至180億美元，預計未來十年將以約6%至10%的複合年成長率成長。這一成長主要得益於人們對感染疾病的認知不斷提高、多重檢測技術的廣泛應用以及新型分子診斷平台的持續開發。

分子診斷檢測在臨床決策中發揮著至關重要的作用，它能夠準確識別病原體，並支持選擇合適的治療方法。快速檢測病原體可以改善患者預後，減少不必要的頻譜抗生素使用，並支持醫療機構的感染控制工作。

技術概述

分子診斷檢測利用擴增和定序技術來檢測病原體特異性核酸序列。聚合酵素鏈鎖反應（PCR）因其高靈敏度和對多種病原體的適用性，是應用最廣泛的分子診斷方法。即時PCR技術能夠快速檢測和定量臨床檢體中的病原體DNA或RNA。

恒溫環型核酸擴增（LAMP）和轉錄媒介增幅（TMA）等溫擴增技術為PCR提供了替代方案，無需複雜的循環設備即可實現快速檢測。這些技術在分散式檢測和患者現場檢測環境中尤其有用。

次世代定序（NGS）技術正日益廣泛地應用於病原體鑑定、流行病學監測和抗菌藥物抗藥性標記的檢測。基於定序的診斷方法能夠實現對病原體的無偏檢測，並識別與抗藥性相關的基因突變。

多重診斷試劑盒能夠同時檢測單一患者檢體中的多種病原體。針對特定症候群的診斷試劑盒常用於感染疾病、感染疾病和血液感染疾病，為臨床醫生提供全面的診斷資訊。

自動化和樣品製備技術的進步提高了工作流程效率，縮短了獲得結果所需的時間。

臨床應用

分子診斷技術在臨床檢查室中被廣泛用於各種臨床環境下感染疾病的檢測和管理。呼吸道傳染病檢查是其中應用最廣泛的領域之一，包括流感病毒、呼吸道融合細胞病毒（RSV）、SARS-CoV-2和其他呼吸道病原體的檢測。

性行為感染(STI) 檢測也是一個重要的應用領域，包括檢測沙眼披衣菌、淋病奈瑟菌、人類乳突病毒 (HPV) 和單純皰疹病毒 (HSV) 等病原體。

胃腸道病原體檢測用於檢測與腹瀉和食物中毒相關的細菌、病毒和寄生蟲。

血液傳染病檢查有助於快速識別與敗血症相關的病原體，以便能夠及時治療性介入。

醫院感染檢測透過識別抗藥性金黃色葡萄球菌(MRSA) 和困難梭狀桿菌等微生物來支持感染控制計畫。

分子診斷技術也被用於檢測抗生素抗藥性標記，從而支持選擇合適的抗生素和製定合理的用藥方案。

公共衛生實驗室利用分子診斷技術監測新興感染疾病和病原體的演變。

市場促進因素

多種因素正在推動針對感染疾病的臨床檢查室分子診斷市場的成長。

感染疾病日益普遍，對準確診斷檢測的需求也隨之增加。

人們對抗生素抗藥性的認知不斷提高，因此對快速病原體鑑定和抗藥性檢測的需求也日益成長。

多項目症候群篩檢方案的擴展提高了診斷效率，縮短了開始治療的時間。

分子生物學技術的進步使得開發新的診斷檢測方法成為可能。

對公共衛生基礎設施投入的增加正在支持分子檢測能力的擴展。

診斷檢測的去中心化正在擴大分子技術在臨床實務中的應用。

將分子診斷納入臨床指引正在加速醫療專業人員對分子診斷的採用。

國際旅行和人口流動性的增加正在提高新興感染疾病傳播的風險。

市場結構與細分

臨床檢測中的分子感染疾病診斷市場可以按技術、應用、最終用戶和地區進行細分。

按技術分類，基於 PCR 的檢測方法佔最大佔有率，其次是等溫擴增技術和基於定序的診斷方法。

按應用領域分類，呼吸道傳染病檢查是檢測數量最多的領域之一，其次是性行為感染感染、胃腸道感染疾病、血液感染疾病和院內獲得性感染。

最終用戶包括醫院檢查室、獨立實驗室、公共衛生實驗室、診所檢查室和分散式檢查環境。

北美是最大的區域市場，這得益於其完善的醫療保健基礎設施和分子檢測技術的高普及率。

歐洲憑藉著完善的檢測體系，已成為重要的市場。

由於對醫療基礎設施和診斷技術的投資增加，亞太市場正在擴張。

競爭格局

分子感染疾病診斷市場包括跨國診斷公司、專業分子診斷開發公司和新興生物技術公司。

競爭程度取決於靈敏度、特異性、所需時間、易用性以及所提供的測試選項的廣度等因素。

設備部署策略通常包括長期試劑供應合約，以提供持續的收入來源。

各公司正日益開發集樣品製備、擴增、檢測和軟體分析於一體的整合診斷平台。

數位化連結和數據管理能力正日益成為重要的競爭優勢。

診斷公司與公共衛生組織之間的策略夥伴關係正在支持新型檢測解決方案的開發。

未來展望

隨著快速檢測感染疾病病原體和改進合理使用抗生素在醫療保健系統中變得越來越重要，針對感染疾病的臨床檢查室分子診斷市場預計將繼續擴大。

隨著臨床醫生越來越希望從單次檢測中獲得全面的診斷訊息，多重檢測板的應用預計將會更加廣泛。

定序技術有可能在疫情監測和抗藥性監測中發揮越來越重要的作用。

照護現場分子診斷平台有可能改善分散式醫療環境中的偵測服務。

人工智慧（AI）工具有望提高對複雜分子診斷數據的解讀能力。

整體而言，分子診斷已成為現代感染疾病控制和公共衛生緊急準備的關鍵要素。分子生物學技術、自動化和數據分析的不斷進步預計將支撐市場的持續成長。

目錄

第1章 市集指南

  • 情境分析
  • 人工智慧的影響

第2章：引言與市場定義

  • 市場定義
  • 調查方法
  • 展望：醫療保健和體外診斷行業
  • 體外診斷產品的特性
  • 未來體外診斷醫療器材

第3章：感染疾病－病原體指南

  • 感染疾病病原體—整體情況
    • 病毒
    • 細菌
    • 真菌
    • 寄生蟲
    • 朊病毒
    • 毒性
    • 感染
  • 新冠病毒
    • 嚴重急性呼吸症候群（SARS）
    • 中東呼吸道症候群（MERS）
    • 新冠病毒（COVID-19），SARS-CoV-2病毒

第4章 行業概覽

  • 參與企業充滿活力的市場
    • 學術研究辦公室
    • 診斷測試開發人員
    • 測量儀器供應商
    • 化學品/試劑供應商
    • 病理檢測用品供應商
    • 獨立臨床實驗室
    • 國家/地區公共研究機構
    • 醫院檢查室
    • 醫師診所檢查室(POLS)
    • 審計機構
    • 認證機構
  • 臨床檢測市場細分
  • 產業結構

第5章 市場趨勢

  • 成長促進因素
  • 成長阻礙因素
  • 測量儀器、自動化和診斷技術的發展趨勢

第6章：臨床檢查室分子診斷的最新趨勢

第7章主要企業

  • Abbott Laboratories
  • Agilent
  • Altona Diagnostics
  • Anitoa
  • Autonomous Medical Devices
  • Beckman Coulter Diagnostics（Danaher）
  • Becton, Dickinson and Company
  • BioGX
  • Biomatik
  • bioMerieux Diagnostics
  • Bio-Rad Laboratories, Inc
  • Cepheid（Danaher）
  • Diasorin SpA
  • DNAe
  • Flow Health
  • Global Access Diagnostics
  • Great Basin Scientific, Inc
  • Hologic
  • Novacyt
  • Novus Diagnostics
  • Oncimmune
  • One Codex
  • OraSure Technologies
  • Prometheus Laboratories
  • Qiagen
  • QuidelOrtho
  • R-Biopharm AG
  • Response Biomedical
  • Revvity
  • Roche Diagnostics
  • Siemens Healthineers
  • Thermo Fisher Scientific
  • Vela Diagnostics
  • Veredus Laboratories
  • YD Diagnostics
  • Zhejiang Orient Gene Biotech

第8章：全球臨床檢查室分子診斷市場

  • 全球市場概覽（按國家/地區分類）
  • 全球市場概覽（按應用領域分類）
  • 區域全球市場概覽

第9章：全球臨床檢查室分子診斷市場－按應用領域分類

  • 呼吸系統
  • 血源性病毒
  • 移植
  • 院內感染
  • 生殖醫學
  • C19 單鏈
  • 腦膜炎
  • 消化系統
  • 局部的

第10章：全球臨床檢查室分子診斷市場－按地區分類

  • 醫院檢查室
  • 門診檢查室
  • 醫療網站
  • 其他

第11章附錄

表格一覽

圖表清單

簡介目錄
Product Code: CLINMDxID 426

Report Overview:

Molecular diagnostics for infectious disease testing represent one of the most dynamic and strategically important segments of the clinical laboratory testing market. These diagnostic technologies detect nucleic acids associated with pathogens such as viruses, bacteria, fungi, and parasites, enabling rapid and highly accurate identification of infectious agents. Molecular diagnostic methods offer significant advantages over traditional microbiology approaches by providing improved sensitivity, specificity, and faster time to result, enabling clinicians to initiate appropriate treatment more quickly and reduce transmission of infectious diseases.

The global market for clinical laboratory molecular diagnostics for infectious disease testing is estimated to exceed approximately USD 12-18 billion annually, with projected compound annual growth rates in the range of approximately 6-10% over the next decade. Growth is supported by increasing awareness of infectious disease risks, expanding adoption of multiplex testing technologies, and continued development of new molecular diagnostic platforms.

Molecular diagnostic testing plays an essential role in clinical decision-making by enabling accurate pathogen identification and supporting appropriate therapeutic selection. Rapid detection of infectious organisms can improve patient outcomes, reduce unnecessary use of broad-spectrum antibiotics, and support infection control efforts within healthcare settings.

Technology Overview

Molecular diagnostic tests detect pathogen-specific nucleic acid sequences using amplification or sequencing technologies. Polymerase chain reaction (PCR) represents the most widely used molecular diagnostic method due to its high sensitivity and adaptability across a broad range of pathogens. Real-time PCR technologies allow rapid detection and quantification of pathogen DNA or RNA in clinical samples.

Isothermal amplification technologies such as loop-mediated isothermal amplification (LAMP) and transcription-mediated amplification (TMA) provide alternatives to PCR that enable rapid testing without complex thermal cycling equipment. These technologies are particularly valuable for decentralized and near-patient testing environments.

Next-generation sequencing (NGS) technologies are increasingly used for pathogen identification, epidemiological surveillance, and detection of antimicrobial resistance markers. Sequencing-based diagnostics enable unbiased detection of pathogens and identification of genetic mutations associated with drug resistance.

Multiplex molecular diagnostic panels enable simultaneous detection of multiple pathogens from a single patient sample. Syndromic testing panels are commonly used for respiratory infections, gastrointestinal infections, and bloodstream infections, providing clinicians with comprehensive diagnostic information.

Advances in automation and sample preparation technologies have improved workflow efficiency and reduced time to result.

Clinical Applications

Clinical laboratory molecular diagnostics are widely used in the detection and management of infectious diseases across multiple clinical settings. Respiratory infection testing represents one of the largest segments, including detection of pathogens such as influenza virus, respiratory syncytial virus (RSV), SARS-CoV-2, and other respiratory pathogens.

Sexually transmitted infection (STI) testing represents another important application area, including detection of pathogens such as Chlamydia trachomatis, Neisseria gonorrhoeae, human papillomavirus (HPV), and herpes simplex virus (HSV).

Gastrointestinal pathogen testing is used to detect bacterial, viral, and parasitic organisms associated with diarrheal disease and foodborne illness.

Bloodstream infection testing supports rapid identification of pathogens associated with sepsis, enabling timely therapeutic intervention.

Hospital-acquired infection testing supports infection control programs by identifying organisms such as methicillin-resistant Staphylococcus aureus (MRSA) and Clostridioides difficile.

Molecular diagnostics are also used for detection of antimicrobial resistance markers, supporting appropriate antibiotic selection and stewardship programs.

Public health laboratories use molecular diagnostics for surveillance of emerging infectious diseases and monitoring of pathogen evolution.

Market Drivers

Several factors are driving growth in the clinical laboratory molecular diagnostics for infectious disease market.

Increasing prevalence of infectious diseases continues to create demand for accurate diagnostic testing.

Growing awareness of antimicrobial resistance is increasing demand for rapid pathogen identification and resistance detection.

Expansion of multiplex syndromic testing panels is improving diagnostic efficiency and reducing time to treatment.

Advances in molecular biology technologies are enabling development of new diagnostic assays.

Increased investment in public health infrastructure is supporting expansion of molecular testing capacity.

Decentralization of diagnostic testing is expanding use of molecular technologies in point-of-care settings.

Integration of molecular diagnostics into clinical guidelines is supporting adoption by healthcare providers.

Global travel and population mobility increase risk of emerging infectious disease transmission.

Market Structure and Segmentation

The clinical laboratory molecular infectious disease diagnostics market can be segmented by technology, application, end user, and geographic region.

By technology, PCR-based testing represents the largest segment, followed by isothermal amplification technologies and sequencing-based diagnostics.

By application, respiratory infection testing represents one of the highest-volume segments, followed by sexually transmitted infections, gastrointestinal infections, bloodstream infections, and hospital-acquired infections.

End users include hospital laboratories, independent reference laboratories, public health laboratories, physician office laboratories, and decentralized testing environments.

North America represents the largest regional market due to established healthcare infrastructure and high adoption of molecular testing technologies.

Europe represents a significant market supported by well-developed laboratory systems.

Asia-Pacific markets are expanding due to increasing investment in healthcare infrastructure and diagnostic technologies.

Competitive Landscape

The molecular infectious disease diagnostics market includes multinational diagnostic companies, specialized molecular diagnostics developers, and emerging biotechnology firms.

Competition is driven by assay sensitivity, specificity, turnaround time, ease of use, and breadth of test menu.

Instrument placement strategies often involve long-term reagent supply agreements that generate recurring revenue streams.

Companies are increasingly developing integrated diagnostic platforms combining sample preparation, amplification, detection, and software analysis.

Digital connectivity and data management capabilities are becoming increasingly important competitive differentiators.

Strategic partnerships between diagnostic companies and public health organizations support development of new testing solutions.

Future Outlook

The clinical laboratory molecular diagnostics for infectious disease market is expected to continue expanding as healthcare systems emphasize rapid detection of infectious pathogens and improved antimicrobial stewardship.

Multiplex testing panels are expected to become increasingly widely adopted as clinicians seek comprehensive diagnostic information from single tests.

Sequencing technologies may play an expanding role in outbreak surveillance and antimicrobial resistance monitoring.

Point-of-care molecular diagnostic platforms may improve access to testing in decentralized healthcare settings.

Artificial intelligence tools are expected to improve interpretation of complex molecular diagnostic data.

Overall, molecular diagnostics represent a critical component of modern infectious disease management and public health preparedness. Continued advances in molecular biology technologies, automation, and data analytics are expected to support sustained market growth.

Table of Contents

1 Market Guides

  • 1.1 Situation Analysis
  • 1.2 Impact of Artificial Intelligence

2 Introduction and Market Definition

  • 2.1 Market Definition
    • 2.1.1 Market Size
    • 2.1.2 Currency
    • 2.1.3 Years
  • 2.2 Methodology
    • 2.2.1 Methodology
    • 2.2.2 Sources
    • 2.2.3 Authors
  • 2.3 Perspective: Healthcare and the IVD Industry
    • 2.3.1 Global Healthcare Spending
    • 2.3.2 Spending on Diagnostics
    • 2.3.3 Important Role of Insurance for Diagnostics
  • 2.4 The Nature of the IVD Product
    • 2.4.1 Features Overview
    • 2.4.2 The Misunderstood Feature
    • 2.4.3 Regulation
    • 2.4.4 The Newest Feature
    • 2.4.5 The Oldest Feature
    • 2.4.6 All About Scope
    • 2.4.7 Why Turnaround is Becoming More Important
    • 2.4.8 The Role of Trust
  • 2.5 The IVD Product of the Future

3 Infectious Diseases - Guide to the Pathogens

  • 3.1 Infectious Disease Pathogens - The Big Picture
    • 3.1.1 Viruses
    • 3.1.2 Bacteria
    • 3.1.3 Fungi
    • 3.1.4 Parasites
    • 3.1.5 Prions
    • 3.1.6 Virulence
    • 3.1.7 Transmission
  • 3.2 The Coronavirus
    • 3.2.1 Severe acute respiratory syndrome (SARS)
    • 3.2.2 Middle East respiratory syndrome (MERS)
    • 3.2.3 COVID-19. The SARS CoV 2 Virus.
      • 3.2.3.1 Signs and symptoms
      • 3.2.3.2 Transmission
      • 3.2.3.3 Diagnosis
      • 3.2.3.4 Prevention
      • 3.2.3.5 Management
      • 3.2.3.6 Prognosis

4 Industry Overview

  • 4.1 Players in a Dynamic Market
    • 4.1.1 Academic Research Lab
    • 4.1.2 Diagnostic Test Developer
    • 4.1.3 Instrumentation Supplier
    • 4.1.4 Chemical/Reagent Supplier
    • 4.1.5 Pathology Supplier
    • 4.1.6 Independent Clinical Laboratory
    • 4.1.7 Public National/regional Laboratory
    • 4.1.8 Hospital Laboratory
    • 4.1.9 Physicians Office Lab (POLS)
    • 4.1.10 Audit Body
    • 4.1.11 Certification Body
  • 4.2 The Clinical Laboratory Market Segments
    • 4.2.1 Traditional Market Segmentation
    • 4.2.2 Laboratory Focus and Segmentation
    • 4.2.3 Segmenting the Syndromic Testing Market
  • 4.3 Industry Structure
    • 4.3.1 Hospital Testing Share
    • 4.3.2 Economies of Scale
    • 4.3.3 Hospital vs. Central Lab
    • 4.3.4 Physician Office Lab's
    • 4.3.5 Physician's and POCT

5 Market Trends

  • 5.1 Factors Driving Growth
    • 5.1.1 The Nucleic Acid Impact
    • 5.1.2 Population Dynamics
    • 5.1.3 The Developing World
    • 5.1.4 Decentralization
    • 5.1.5 Self Testing
    • 5.1.6 The Need for Speed
  • 5.2 Factors Limiting Growth
    • 5.2.1 Costs and Experience Curve Effects
    • 5.2.2 The Role of ID Prevalence
    • 5.2.3 Wellness
    • 5.2.4 The Impact of Living Standards
  • 5.3 Instrumentation, Automation and Diagnostic Trends
    • 5.3.1 Traditional Automation and Centralization
    • 5.3.2 The New Automation, Decentralization and Point Of Care
    • 5.3.3 Instruments Key to Market Share
    • 5.3.4 Bioinformatics Plays a Role
    • 5.3.5 PCR Takes Command
    • 5.3.6 Next Generation Sequencing Fuels a Revolution
    • 5.3.7 NGS Impact on Pricing
    • 5.3.8 Whole Genome Sequencing, A Brave New World
    • 5.3.9 Companion Diagnostics Blurs Diagnosis and Treatment

6 Clinical Laboratory MDx Infectious Disease Recent Developments

  • 6.1 Recent Developments - Importance and How to Use This Section
    • 6.1.1 Importance of These Developments
    • 6.1.2 How to Use This Section
  • 6.2 Presymptom Health Nabs Funding for Sepsis Test
  • 6.3 FDA Clears BioMerieux GI Panel
  • 6.4 Rapid Infection Diagnostic Launches BSIDx
  • 6.5 Biotia's AI-, Sequencing-Based UTI Test approved
  • 6.6 Delve Bio, Broad Clinical Labs Partner for Metagenomic
  • 6.7 Roche Respiratory Panel Receives FDA EUA
  • 6.8 Genetic Signatures Gets Approval for GI Parasite Panel
  • 6.9 Diasorin Expands Respiratory Panel
  • 6.10 BioMerieux Outlines MDx-Driven Growth
  • 6.11 T2 Biosystems Gets Extended T2Bacteria Panel
  • 6.12 Diasorin Aims to Deliver Updated Instruments, New Assays
  • 6.13 Oxford Nanopore Nabs Investment From BioMerieux
  • 6.14 Day Zero Diagnostics Closes Financing Round
  • 6.15 Spindiag Seeks Investors for Rapid PCR System
  • 6.16 Sorrento Therapeutics Nabs Contract for Dx Platform
  • 6.17 Kephera Planning Menu of Infectious Disease Tests
  • 6.18 Oxford Nanopore and BioMerieux to Develop IDDx
  • 6.19 SD Biosensor Eyes Global Expansion
  • 6.20 Selux Dx Next Gen Phenotyping Gets FDA Clearance
  • 6.21 Takara Developing High-Throughput Multiplex Panels
  • 6.22 BioGX Debuts New Point-of-Care Molecular Testing System
  • 6.23 Nanopath MDx Platform Providing 15-Minute Results
  • 6.24 ProtonDx Commercializing Rapid MDx Instrument
  • 6.25 Hologic Obtains CE Mark for MDx Epstein-Barr, BK Virus Assays
  • 6.26 Pathogenomix Infectious Disease Platform Uses Cloud-Based Analytics, NGS
  • 6.27 Accelerate Diagnostics Anticipates Growth
  • 6.28 Lumos Diagnostics Expanding Test Portfolio
  • 6.29 Study Validates Karius Cell-Free DNA to Detect Hundreds of Pathogens

7 Key Companies

  • 7.1 Abbott Laboratories
  • 7.2 Agilent
  • 7.3 Altona Diagnostics
  • 7.4 Anitoa
  • 7.5 Autonomous Medical Devices
  • 7.6 Beckman Coulter Diagnostics (Danaher)
  • 7.7 Becton, Dickinson and Company
  • 7.8 BioGX
  • 7.9 Biomatik
  • 7.10 bioMerieux Diagnostics
  • 7.11 Bio-Rad Laboratories, Inc
  • 7.12 Cepheid (Danaher)
  • 7.13 Diasorin S.p.A.
  • 7.14 DNAe
  • 7.15 Flow Health
  • 7.16 Global Access Diagnostics
  • 7.17 Great Basin Scientific, Inc
  • 7.18 Hologic
  • 7.19 Novacyt
  • 7.20 Novus Diagnostics
  • 7.21 Oncimmune
  • 7.22 One Codex
  • 7.23 OraSure Technologies
  • 7.24 Prometheus Laboratories
  • 7.25 Qiagen
  • 7.26 QuidelOrtho
  • 7.27 R-Biopharm AG
  • 7.28 Response Biomedical
  • 7.29 Revvity
  • 7.30 Roche Diagnostics
  • 7.31 Siemens Healthineers
  • 7.32 Thermo Fisher Scientific
  • 7.33 Vela Diagnostics
  • 7.34 Veredus Laboratories
  • 7.35 YD Diagnostics
  • 7.36 Zhejiang Orient Gene Biotech

8 The Global Market for Clinical Laboratory MDx Infectious Disease

  • 8.1 Global Market Overview by Country
    • 8.1.1 Table - Global Market by Country
    • 8.1.2 Chart - Global Market by Country
  • 8.2 Global Market by Application - Overview
    • 8.2.1 Table - Global Market by Application
    • 8.2.2 Chart - Global Market by Application - Base/Final Year Comparison
    • 8.2.3 Chart - Global Market by Application - Base Year
    • 8.2.4 Chart - Global Market by Application - End Year
    • 8.2.5 Chart - Global Market by Application - Share by Year
    • 8.2.6 Chart - Global Market by Application - Segments Growth
  • 8.3 Global Market by Place - Overview
    • 8.3.1 Table - Global Market by Place
    • 8.3.2 Chart - Global Market by Place - Base/Final Year Comparison
    • 8.3.3 Chart - Global Market by Place - Base Year
    • 8.3.4 Chart - Global Market by Place - End Year
    • 8.3.5 Chart - Global Market by Place - Share by Year
    • 8.3.6 Chart - Global Market by Place - Segments Growth

9 Global Clinical Laboratory MDx Infectious Disease Markets - By Application

  • 9.1 Respiratory
    • 9.1.1 Table Respiratory - by Country
    • 9.1.2 Chart - Respiratory Growth
  • 9.2 Blood Borne Virus
    • 9.2.1 Table Blood Borne Virus - by Country
    • 9.2.2 Chart - Blood Borne Virus Growth
  • 9.3 Transplant
    • 9.3.1 Table Transplant - by Country
    • 9.3.2 Chart - Transplant Growth
  • 9.4 Hospital Acquired Infections
    • 9.4.1 Table Hospital Acquired Infections - by Country
    • 9.4.2 Chart - Hospital Acquired Infections Growth
  • 9.5 Reproductive Health
    • 9.5.1 Table Reproductive Health - by Country
    • 9.5.2 Chart - Reproductive Health Growth
  • 9.6 C19 Singleplex
    • 9.6.1 Table C19 Singleplex - by Country
    • 9.6.2 Chart - C19 Singleplex Growth
  • 9.7 Meningitis
    • 9.7.1 Table Meningitis - by Country
    • 9.7.2 Chart - Meningitis Growth
  • 9.8 Gastrointestinal
    • 9.8.1 Table Gastrointestinal - by Country
    • 9.8.2 Chart - Gastrointestinal Growth
  • 9.9 Tropical
    • 9.9.1 Table Tropical - by Country
    • 9.9.2 Chart - Tropical Growth

10 Global Clinical Laboratory MDx Infectious Disease Markets - By Place

  • 10.1 Hospital Lab
    • 10.1.1 Table Hospital Lab - by Country
    • 10.1.2 Chart - Hospital Lab Growth
  • 10.2 Outpatient Lab
    • 10.2.1 Table Outpatient Lab - by Country
    • 10.2.2 Chart - Outpatient Lab Growth
  • 10.3 Point of Care
    • 10.3.1 Table Point of Care - by Country
    • 10.3.2 Chart - Point of Care Growth
  • 10.4 Other Place
    • 10.4.1 Table Other Place - by Country
    • 10.4.2 Chart - Other Place Growth

11 Appendices

  • 11.1 Growth of Approved IVD Test Menu
  • 11.2 Growth of Approved Average IVD Test Fee
  • 11.3 The Most Used IVD Assays
  • 11.4 The Highest Grossing Assays
  • 11.5 Laboratory Fees Schedule

Table of Tables

  • Table 1 Key IVD Features
  • Table 2 Features in the Future
  • Table 3 Viral Pathogens and Families
  • Table 4 Characteristics of Coronavirus Pandemic Infections
  • Table 5 COVID-19 Symptoms
  • Table 6 Market Players by Type
  • Table 7 Clinical Laboratory Departments and Segments
  • Table 8 Laboratory Management Focus - Different Approaches
  • Table 9 Key Segmentation Variables Going Forward
  • Table 10 Possible Market Segments of Syndromic Multiplex Market
  • Table 11 Five Factors Driving Growth
  • Table 12 Four Factors Limiting Growth
  • Table 13 Seven Key Diagnostic Laboratory Technology Trends
  • Table 14 - Global Market by Region
  • Table 15 Global Market by Application
  • Table 16 Global Market by Place
  • Table 17 Respiratory by Country
  • Table 18 Blood Borne Virus by Country
  • Table 19 Transplant by Country
  • Table 20 Hospital Acquired Infections by Country
  • Table 21 Reproductive Health by Country
  • Table 22 C19 Singleplex by Country
  • Table 23 Meningitis by Country
  • Table 24 Gastrointestinal by Country
  • Table 25 Tropical by Country
  • Table 26 Hospital Lab by Country
  • Table 27 Outpatient Lab by Country
  • Table 28 Point of Care by Country
  • Table 29 Other Place by Country
  • Table 30 The Most Common Assays
  • Table 31 Largest Revenue Assays
  • Table 32 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 Global Health Care Spending Per Capita
  • Figure 2 The Lab Test Pie
  • Figure 3 Structure of a Typical Virus
  • Figure 4 Mycobacterium Tuberculosis
  • FIGURE 5 STRUCTURE OF CORONAVIRUSES
  • Figure 6 The Road to Diagnostics
  • Figure 7 The Changing Age of The World's Population
  • Figure 8 Health Care Consumption by Age
  • Figure 9 Cancer Incidence - Age at Diagnosis
  • Figure 10 Percentage of World Population Over 65
  • Figure 11 Chart Infectious Disease Decline
  • Figure 12 Centralized vs. Decentralized Laboratory Service
  • Figure 13 A Highly Multiplexed Syndromic Testing Unit
  • Figure 14 The Real Cost to Sequence the Human Genome
  • Figure 15 The Codevelopment Process
  • Figure 16 Global Market Share Chart
  • Figure 17 Global Market by Application - Base vs. Final
  • Figure 18 Global Market by Application Base Year
  • Figure 19 Global Market by Application End Year
  • Figure 20 Application Share by Year
  • Figure 21 Application Segments Growth
  • Figure 22 Global Market by Place - Base vs. Final
  • Figure 23 Global Market by Place Base Year
  • Figure 24 Global Market by Place End Year
  • Figure 25 Place Share by Year
  • Figure 26 Place Segments Growth
  • Figure 27 Respiratory Growth
  • Figure 28 Blood Borne Virus Diagnostics Growth
  • Figure 29 Transplant Growth
  • Figure 30 Hospital Acquired Infections Growth
  • Figure 31 Reproductive Health Growth
  • Figure 32 C19 Singleplex Growth
  • Figure 33 Meningitis Growth
  • Figure 34 Gastrointestinal Growth
  • Figure 35 Tropical Growth
  • Figure 36 Hospital Lab Growth
  • Figure 37 Outpatient Lab Growth
  • Figure 38 Point of Care Growth
  • Figure 39 Other Place Growth
  • Figure 40 IVD Test Menu Growth
  • Figure 41 IVD Test Average Fees - A Ten Year View